[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanna Babalonis, PhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":118},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,67,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643978","phase-1-cannabis-effects-on-opioid-self-administration-100643978",false,"NCT07668635","Cannabis Effects on Opioid Self-Administration","Impact of Cannabis on Opioid Self-Administration","Inclusion Criteria:\n\n* Participants with moderate to severe opioid use disorder who experience opioid withdrawal\n* No allergies or adverse reactions to cannabis or opioids\n* Willing to stay inpatient at the UK Hospital research center for approx. 6 weeks\n\nExclusion Criteria:\n\n* Individuals seeking treatment for opioid use disorder","ALL","18 Years","55 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive\u002Fdesire to take opioids.",[27,28],"Opioid Use Disorder","Cannabis Use",[30,31],"opioid use","cannabis","NOT_YET_RECRUITING","2026-06-19",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":21},"2026-07-30",{"date":40,"type":21},"2031-07-30",{"name":42,"class":43},"Shanna Babalonis, PhD","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":44},"100495342","phase-1-cannabis-and-opioid-use-disorder-100495342","NCT05729932","Cannabis and Opioid Use Disorder","Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Abuse Potential and Safety","Inclusion Criteria:\n\n* Current opioid use disorder\n\nExclusion Criteria:\n\n* Current medical conditions that require medical management",true,{"count":54,"type":21},15,[24],"This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.",[27],"RECRUITING","2026-06-16",{"date":61,"type":36},"2026-06-18",{"date":63,"type":36},"2024-09-10",{"date":65,"type":21},"2027-06-30",{"name":42,"class":43},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100574273","phase-1-opioid-drug-interaction-study-100574273","NCT06757140","Opioid Drug Interaction Study","Opioid Drug Interactions: Safety, Abuse Potential and Pharmacokinetic Effects","Inclusion Criteria:\n\n* English-speaking and literate participants, able to understand and sign Informed Consent Document\n* ages 18 to 55 years old inclusive\n* BMI of greater than\u002Fequal to 17 and approximately less than or equal to 30\n* self-reported opioid use\n* self-reported sedative-like drug use\n* women of childbearing potential must not be pregnant or breastfeeding at screening and be using an effective form of contraception throughout study participation\n* otherwise healthy as determined by the medical\u002Fresearch team based on medical history, physical examination, vital signs, laboratory chemistries (blood chemistry with liver function tests and hematology, urinalysis and microscopic evaluation, 12-lead electrocardiogram)\n* willing and able to comply with all testing requirements defined in the protocol\n* adequate venous access (determined by RN) for pharmacokinetic blood draws\n\nExclusion Criteria:\n\n* physical dependence on alcohol, opioids, benzodiazepines or sedative\u002Fhypnotics requiring medical management\u002Fdetoxification\n* seeking treatment for opioid or any other drug use\n* acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \\[e.g., asthma, COPD\\])\n* clinically significant abnormal ECG (as determined by study physician\u002Fcardiologist)\n* clinically significant abnormal laboratory findings (e.g., liver function tests greater than 3x the upper limits of normal range)\n* current or past history of major psychiatric disorder that would limit ability to participate in the study (e.g., bipolar disorder).\n* recent use of CYP2C9, CYP2D6 and CYP3A4 inhibitor or inducer that is long-acting and not amenable to a wash-out period after enrollment\n* known hypersensitivity to any of the study drugs\n* currently pregnant or breastfeeding\n* currently under parole or probation with urine testing requirements",{"count":75,"type":21},25,[24,77],"PHASE2","This study will examine the effects of doses of opioid\u002Fplacebo and doses of alprazolam\u002Fplacebo, alone and in combination. The primary outcomes are pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) and pharmacokinetic outcomes (from blood samples) to determine the interaction effects of these compounds.",[80,81],"Drug Interactions","Drug Kinetics",[83,84,85,86,87],"inpatient study","opioids","opiates","sedatives","opioid misuse","2026-05-13",{"date":90,"type":36},"2026-05-14",{"date":92,"type":36},"2025-04-01",{"date":94,"type":21},"2029-06-01",{"name":42,"class":43},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":44},"100562288","phase-1-impact-of-daily-oral-cannabis-doses-in-patients-with-cancer-100562288","NCT06601218","Impact of Daily Oral Cannabis Doses in Patients With Cancer","A Phase I Study of the Effects of Cannabis on Cancer Burden: Placebo-Controlled, Double-Blind, Randomized Trial","Example Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced or metastatic solid tumors with any types. This applies to either newly diagnosed cancer or preexisting ones on treatment.\n* Patients with active cancers and currently under any line of treatment (please see notable exceptions in the exclusion criteria - patients taking checkpoint inhibitors and investigational agents will not be eligible - also exclusionary medications).\n* Patients have been taking their current anti-cancer therapy regimen for at least one month prior to enrollment (to ensure no safety or toxicity issues with study drug initiation).\n* Age ≥18 years.\n* ECG and lab values demonstrating adequate organ and marrow function at baseline (pre-study).\n* Negative urine drug screen for all illicit drugs and THC, CBD prior to randomization\n* Ability to understand and the willingness to sign a written informed consent document\n* Individuals able to become pregnant will agree to practice an effective form of contraception (e.g., oral birth control pills, condoms, abstinence) for the duration of enrollment (note: urine pregnancy testing will occur monthly)\n\nExclusion Criteria:\n\n* History of hypersensitivity to cannabis or cannabinoids\n* Current, regular use of cannabis\u002Fmarijuana or THC-containing medications (dronabinol, nabilone) or cannabidiol (Epidiolex) or over-the-counter (OTC) CBD oil.\n* Concomitant use of checkpoint inhibitors (e.g., anti-PD1, PDL1, CTLA4) or other drugs for which an cannabinoid interaction may occur.\n* Current use of investigational agents, \\<3 months after the use of investigational agents\n* Cardiac conditions contraindicated for cannabis use\n* Diagnosis of HPV-related cancer, as there is some evidence that cannabis is contraindicated\n* Allergy to any constituent\u002Fingredient contained in the edible dose\n* Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements (e.g., bipolar disorder, psychosis, severe depression\u002Fanxiety).\n* Pregnant or breastfeeding (note: participants will be tested for pregnancy (urine sample) once per month during enrollment)\n* Current moderate\u002Fsevere drug or alcohol use disorder (including cannabis use disorder), positive urine drug screen for illicit drugs or cannabis, or positive alcohol (breathalyzer) during screening\n* History of seizure disorder, epilepsy (controlled or uncontrolled)\n* Current legal obligations (parole, probation, incarceration, urine drug screen requirements as part of parole\u002Fprobation\u002Fprevious incarceration)\n* Currently enrolled in substance use treatment\n* Self-reported cannabis and synthetic cannabinoid use in the past 30 days (medical or non-medical use is exclusionary)\n* Self-reported illicit drug use in past 60 days (ex: methamphetamine, heroin, illicit fentanyl)\n* Self-reported daily alcohol use\n* Providing a urine sample testing positive for cannabinoids (THC, CBD) or synthetic cannabinoids (K2, Spice-like compounds)\n* Providing a sample testing positive for alcohol (breathalyzer) or non-medical use of other drugs (methamphetamine, cocaine) during screening; testing positive during enrollment will lead to discontinuation of the participant's enrollment\n* No access to internet\u002Fdata or devices needed to participate in daily video calls",{"count":104,"type":21},80,[24],"This study will enroll patients with cancer and participants will be randomized to receive one dose of cannabis for approximately 4 months. There is a 3\u002F4 (or 75%) chance that a participant will receive an active cannabis dose in the study. There is a 1\u002F4 (or 25% chance) that a participant will receive a placebo dose (meaning a blank dose\u002Fno cannabis\u002Fno active drug). The goals of this study are to determine 1) the safety and tolerability of cannabis in individuals with cancer and 2) if cannabis can help with the side effects of cancer and cancer treatment - including nausea and vomiting, appetite, pain, sleep, and quality of life.",[108,109],"Cancer","Cancers, Pain","2025-06-23",{"date":112,"type":36},"2025-06-24",{"date":114,"type":36},"2025-06-17",{"date":116,"type":21},"2030-12-01",{"name":42,"class":43},""]